Patent Foramen Ovale and Cryptogenic Strokes in the Stroke in Young Fabry Patients Study

Background and Purpose— A patent foramen ovale (PFO) is disproportionately prevalent in patients with cryptogenic stroke. Without alternative explanations, it is frequently considered to be causative. A detailed stratification of these patients may improve the identification of incidental PFO. Methods— We investigated the PFO prevalence in 3497 transient ischemic attack and ischemic stroke patients aged 18 to 55 years in the prospective multicenter SIFAP1 study (Stroke in Young Fabry Patients 1) using the ASCO classification. Patients without an obvious cause for transient ischemic attack/stroke (ASCO 0) were divided into subgroups with and without vascular risk factors (ASCO 0+ and 0−). In addition, we looked for PFO-related magnetic resonance imaging lesion patterns. Results— PFO was identified in 25% of patients. Twenty percent of patients with a definite or probable cause of transient ischemic attack/stroke (≥1 grade 1 or 2 ASCO criterion; n=1769) had a PFO compared with 29% of cryptogenic stroke patients (ASCO 0 and 3; n=1728; P<0,001); subdivision of cryptogenic strokes revealed a PFO in 24% of 978 ASCO 3 patients (n.s. versus ASCO 1 and 2) and a higher prevalence of 36% in 750 ASCO 0 cases (P<0.001 versus ASCO 3 and versus ASCO 1 and 2). PFO was more commonly observed in ASCO 0− (n=271) than in ASCO 0+ patients (n=479; 48 versus 29%; P<0.001). There was no PFO-associated magnetic resonance imaging lesion pattern. Conclusions— Cryptogenic stroke patients demonstrate a heterogeneous PFO prevalence. Even in case of less conclusive diseases like nonstenotic arteriosclerosis, patients should preferentially be considered to have a non-PFO-mediated stroke. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00414583.

[1]  S. Sacco,et al.  Prevalence of Patent Foramen Ovale in Ischaemic Stroke in Italy: Results of SISIFO Study , 2015, Cerebrovascular Diseases.

[2]  D. Kent,et al.  Recurrent stroke predictors differ in medically treated patients with pathogenic vs other PFOs , 2014, Neurology.

[3]  T. Meinertz,et al.  Predictors of recurrent stroke after percutaneous closure of patent foramen ovale. , 2014, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[4]  G. Eslick,et al.  Stroke prevention by percutaneous closure of patent foramen ovale: a meta-analytic review. , 2014, International journal of cardiology.

[5]  G. Hankey Secondary stroke prevention , 2014, The Lancet Neurology.

[6]  C. Kessler,et al.  MRI in acute cerebral ischemia of the young , 2013, Neurology.

[7]  D. Kent,et al.  An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke , 2013, Neurology.

[8]  C. DeCarli,et al.  Patent foramen ovale, subclinical cerebrovascular disease, and ischemic stroke in a population-based cohort. , 2013, Journal of the American College of Cardiology.

[9]  J. DiNicolantonio,et al.  Stroke prevention by percutaneous closure of patent foramen ovale: a systematic review and meta-analysis , 2013, Heart.

[10]  J. Carroll,et al.  Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. , 2013, The New England journal of medicine.

[11]  G. Schuler,et al.  Percutaneous closure of patent foramen ovale in cryptogenic embolism. , 2013, The New England journal of medicine.

[12]  D. Kent,et al.  Neuroimaging Findings in Cryptogenic Stroke Patients With and Without Patent Foramen Ovale , 2013, Stroke.

[13]  G. Deuschl,et al.  Acute Cerebrovascular Disease in the Young: The Stroke in Young Fabry Patients Study , 2013, Stroke.

[14]  R. Felberg,et al.  Closure or medical therapy for cryptogenic stroke with patent foramen ovale. , 2012, The New England journal of medicine.

[15]  P. Heuschmann,et al.  Protocol and Methodology of the Stroke in Young Fabry Patients (sifap1) Study: A Prospective Multicenter European Study of 5,024 Young Stroke Patients Aged 18–55 Years , 2010, Cerebrovascular Diseases.

[16]  J. Tobis,et al.  The Association of Patent Foramen Ovale Morphology and Stroke Size in Patients With Paradoxical Embolism , 2010, Circulation. Cardiovascular interventions.

[17]  S. Homma,et al.  Patent Foramen Ovale and Stroke , 2005, Circulation.

[18]  B. Hemmer,et al.  Lesion patterns in patients with cryptogenic stroke with and without right‐to‐left‐shunt , 2009, European journal of neurology.

[19]  H. Diener,et al.  Current Management and Risk of Recurrent Stroke in Cerebrovascular Patients with Right-to-Left Cardiac Shunt , 2009, Cerebrovascular Diseases.

[20]  C. Bode,et al.  Patent Foramen Ovale and Cryptogenic Stroke: A Matter of Age? , 2009, Seminars in thrombosis and hemostasis.

[21]  D. Kent,et al.  Patent Foramen Ovale in Cryptogenic Stroke: Incidental or Pathogenic? , 2009, Stroke.

[22]  J. Martí-Fàbregas,et al.  Recurrent Stroke and Massive Right-to-Left Shunt: Results From the Prospective Spanish Multicenter (CODICIA) Study , 2008, Stroke.

[23]  B. Hemmer,et al.  Lack of association between right-to-left shunt and cerebral ischemia after adjustment for gender and age , 2008, Journal of Negative Results in Biomedicine.

[24]  M. Olschewski,et al.  Patent foramen ovale and cryptogenic stroke in older patients. , 2007, The New England journal of medicine.

[25]  R. Sacco,et al.  Patent foramen ovale and the risk of ischemic stroke in a multiethnic population. , 2007, Journal of the American College of Cardiology.

[26]  M. Cheitlin Patent Foramen Ovale: Innocent or Guilty? Evidence From a Prospective Population-Based Study , 2007 .

[27]  À. Rovira,et al.  Stroke Patients With Cardiac Atrial Septal Abnormalities: Differential Infarct Patterns on DWI , 2006, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[28]  E. Radue,et al.  Diffusion-Weighted Imaging in Stroke Attributable to Patent Foramen Ovale: Significance of Concomitant Atrial Septum Aneurysm , 2006, Stroke.

[29]  M. Kaps,et al.  Embolic Lesion Pattern in Stroke Patients With Patent Foramen Ovale Compared With Patients Lacking an Embolic Source , 2006, Stroke.

[30]  W. O'Fallon,et al.  Population-based study of the relationship between patent foramen ovale and cerebrovascular ischemic events. , 2006, Mayo Clinic proceedings.

[31]  M. Topcuoglu Practice Parameter: Recurrent stroke with patent foramen ovale and atrial septal aneurysm: Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2004, Neurology.

[32]  S. Kasner,et al.  Practice Parameter: Recurrent stroke with patent foramen ovale and atrial septal aneurysm: Report of the Quality Standards Subcommittee of the American Academy of Neurology* , 2004, Neurology.

[33]  R. Sacco,et al.  Effect of Medical Treatment in Stroke Patients With Patent Foramen Ovale: Patent Foramen Ovale in Cryptogenic Stroke Study , 2002, Circulation.

[34]  J. Coste,et al.  Clinical and Imaging Findings in Cryptogenic Stroke Patients With and Without Patent Foramen Ovale: The PFO-ASA Study , 2002 .

[35]  J. Coste,et al.  Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen ovale: the PFO-ASA Study. Atrial Septal Aneurysm. , 2002, Stroke.

[36]  J. Coste,et al.  Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. , 2001, The New England journal of medicine.

[37]  I. Bone,et al.  Interatrial septal abnormalities and stroke , 2000, Neurology.

[38]  I. Palacios,et al.  Closure of patent foramen ovale for paradoxical emboli: intermediate-term risk of recurrent neurological events following transcatheter device placement. , 2000, Journal of the American College of Cardiology.

[39]  R. Sacco,et al.  Patent Foramen Ovale as a Risk Factor for Cryptogenic Stroke , 1992, Annals of Internal Medicine.

[40]  P. Lechat,et al.  Prevalence of patent foramen ovale in patients with stroke. , 1988, The New England journal of medicine.